|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The Fc-fusion protein atacicept is currently under clinical investigation for its biotherapeutic application in autoimmune diseases owing to its ability to bind the two cytokines B-Lymphocyte Stimulator (BLyS) and A PRoliferation-Inducing Ligand (APRIL).
|
31349756 |
2020 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The two related tumor necrosis factor members a proliferation-inducing ligand (APRIL) and B-cell activation factor (BAFF) are currently targeted in autoimmune diseases as B-cell regulators.
|
30635946 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Associations of BAFF with Th2 profile cytokines and disease activity, as well as APRIL with Th1 profile cytokines and organ damage, suggest that BAFF and APRIL generated in the autoimmunity context could through still unknown mechanisms, modulate the microenvironment, and perpetuate the inflammatory response, autoantibody production and organ damage observed in SLE patients.
|
30467093 |
2019 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It is possible that the overexpression of BAFF and APRIL contributes to the pathogenesis of autoimmune diseases.
|
30941763 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We will discuss expectations deriving from APRIL targeting in autoimmune diseases.
|
30385081 |
2018 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression profile of BAFF and APRIL in MN is similar to that of other autoimmune disease, which affects the kidney outcomes.
|
29423047 |
2018 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF-APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity.
|
25505277 |
2015 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The B-cell survival factors APRIL and BLyS are important for B-cell maturation and activation and contribute to human autoimmune diseases.
|
20890272 |
2011 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), essential factors for B cell survival are elevated in systemic autoimmune diseases and correlated with clinical findings.
|
19824872 |
2009 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
BAFF can also, in autoimmune disease form heterotrimers with APRIL but the control and function of these heterotrimers remain unclear.
|
18295728 |
2008 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
CVID subjects had markedly increased serum levels of BAFF (p<0.0001), APRIL (p<0.0001), and TACI (p=0.001) but there was no relationship between levels and autoimmunity, lymphadenopathy, splenomegaly, B cell numbers, or mutations in TACI.
|
17556024 |
2007 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) enhance autoimmune disease by sustaining B cell activation.
|
16239971 |
2005 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE.
|
15308519 |
2004 |
|
Autoimmune Diseases
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
APRIL and BAFF are involved in a variety of tumor and autoimmune diseases, including B-cell malignancies.
|
15070697 |
2004 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers.
|
12370363 |
2002 |